Search | IOVS | ARVO Journals

iovs

Issues
Topics
For Authors
About
- Editorial Board

Journals Home

MANAGE ALERTS

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

To View More...

Purchase this article with an account.

or

Subscribe Now

Issues
Topics
For Authors
About
- Editorial Board

Narrow View

NARROW

Content Type

Meeting Abstract (12)
Journal Articles (1)

Journal

Investigative Ophthalmology & Visual Science (13)

Article Type

ARVO Annual Meeting Abstract (12)
Physiology and Pharmacology (1)

Topics

Cornea (1)
External Eye Disease (1)
Eye Anatomy and Disorders (1)
Glaucoma (1)
Pharmacology (1)

Tags

cyclosporine (1)
eye (1)
fluid flow (1)
glycoproteins (1)
intraocular pressure (1)
ocular lubricants (1)
oryctolagus cuniculus (1)

Specify Date Range

From: To: Apply

Showing 1 – 13 of 13

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract March 2012

Lacritin, a Novel Tear Glycoprotein, is an Effective Topical Antimicrobial Agent in an Animal Model

Alireza Hosseini; Frank A. Lattanzio, Jr.; Sandeep S. Samudre; John D. Sheppard, Jr.; Gordon W. Laurie; Robert L. McKown; Patricia B. Williams

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):6266.

ARVO Annual Meeting Abstract March 2012

Long-term Treatment with Nutritional Supplements Containing Gamma Linolenic Acid and Omega 3 Fatty acids Improve Moderate to Severe Keratoconjunctivitis Sicca

John D. Sheppard, Jr.; Stephen C. Pflugfelder; Ruhi Singh; Andrew J. McClellan; Mitchell P. Weikert; Stephen V. Scoper; Thomas J. Joly; Dayna M. Lago; Walter O. Whitley

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):581.

Physiology and Pharmacology August 2011

Lacritin, a Novel Human Tear Glycoprotein, Promotes Sustained Basal Tearing and Is Well Tolerated

PDF

Sandeep Samudre; Frank A. Lattanzio, Jr; Victoria Lossen; Alireza Hosseini; John D. Sheppard, Jr; Robert L. McKown; Gordon W. Laurie; Patricia B. Williams
TAGS: cyclosporine, glycoproteins, ocular lubricants, oryctolagus cuniculus, eye, fluid flow, intraocular pressure
Invest. Ophthalmol. Vis. Sci.. 2011; 52(9):6265-6270. https://doi.org/10.1167/iovs.10-6220

ARVO Annual Meeting Abstract April 2011

Hypotony in patients with uveitis: The Multicenter Uveitis Steroid Treatment Trial

H Nida Sen; Lea T. Drye; Debra A. Goldstein; Theresa A. Larson; Pauline T. Merrill; Peter Reed Pavan; John D. Sheppard, Jr.; Alyce Burke; Sunil K. Srivastava; Douglas A. Jabs

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):4269.

ARVO Annual Meeting Abstract April 2009

Expression of BFGF and IL-1 Alpha in Tears of Galactosemic Rats: Implications for Wound Healing and Neovascularization

M. Wertheimer; J. Helis; S. Hahto; J. D. Sheppard, Jr.; T. A. Jacot; F. A. Lattanzio, Jr.; P. B. Williams; J. L. Jacot

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):545.

ARVO Annual Meeting Abstract April 2009

Azithromycin Alters ProMMP-2 and TIMP-1 Following Corneal Wounding in an Experimental Animal Model of Diabetic Ocular Complications

J. L. Jacot; T. A. Jacot; S. Hahto; J. Helis; C. J. Sheppard; J. D. Sheppard, Jr.; F. A. Lattanzio, Jr.; P. B. Williams

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):2663.

ARVO Annual Meeting Abstract April 2009

Lacritin, a Novel Tear Glycoprotein, Is More Efficacious and Better Tolerated Than Cyclosporin

V. Lossen; S. S. Samudre; D. J. Campbell; J. D. Sheppard, Jr.; R. C. McKown; G. W. Laurie; P. B. Williams; F. A. Lattanzio, Jr.

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):4662.

ARVO Annual Meeting Abstract May 2008

Loteprednol Etabonate Ophthalmic Suspension 0.2% (ALREX®) and Olopatadine Hydrochloride Ophthalmic Solution 0.1% (PATANOL®) in the Treatment of Allergic Conjunctivitis

E. H. Koo; S. S. Samudre; P. B. Williams; F. A. Lattanzio, Jr.; J. D. Sheppard, Jr.

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):422.

ARVO Annual Meeting Abstract May 2008

Topical Loteprednol 0.5% Induction Therapy Improves Topical Cyclosporine Emulsion Tolerability in Chronic Dry Eye Disease

J. D. Sheppard, Jr.; E. D. Donnenfeld

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):99.

ARVO Annual Meeting Abstract May 2008

Evaluation of MMP2/9 Modulation by Azithromycin and DuraSite on Human Corneal Epithelial Cells and Bovine Corneal Endothelial Cells in vitro

J. L. Jacot; T. A. Jacot; J. D. Sheppard, Jr.; F. A. Lattanzio; P. B. Williams; K. Brubaker

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):1985.

ARVO Annual Meeting Abstract May 2008

Loteprednol Etabonate (Lotemax, 0.5%) Reduces Inflammatory Response Associated With Pterygium Progression

H. T. Nguyen; S. S. Samudre; F. A. Lattanzio, Jr.; P. B. Williams; J. D. Sheppard, Jr.

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):6027.

ARVO Annual Meeting Abstract May 2008

Topical Phosphorodiamidate Morpholino Oligomer Antisense Compounds Effectivly Delay Cornea Rejection in a Transplant Rat Model

J. T. Doss, Jr.; A. Hosseini; F. A. Lattanzio, Jr.; S. S. Samudre; J. Davis; J. D. Sheppard, Jr.; P. B. Williams; P. Iverson; P. O'Hanley

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):5764.

ARVO Annual Meeting Abstract May 2007

Topical Phosphorodiamidate Morpholino Oligomer Anti-Sense Compounds Penetrate the Cornea Without Toxic Effects

J. L. Schneider; F. A. Lattanzio, Jr.; S. S. Samudre; A. Hosseini; J. D. Sheppard, Jr.; P. B. Williams; P. Iversen; P. O'Hanley

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):204.

« Previous

Advertisement

Follow @ARVOiovs

IOVS Home
Issues
Topics
For Authors
About
- Editorial Board

Online ISSN: 1552-5783

Investigative Ophthalmology & Visual Science
Journal of Vision
Translational Vision Science & Technology

JOURNALS HOME
TOPICS
ABOUT ARVO JOURNALS

Copyright © 2025 Association for Research in Vision and Ophthalmology.

Access Provided By:
MIT Libraries

Forgot password?

To View More...

Purchase this article with an account.

Create an Account

or

Subscribe Now

×

×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept